DL
Dhandapani Lokesh
About Dhandapani Lokesh
Data last updated:
Dhandapani Lokesh has experience in corporate governance. Holds Additional Director role. Currently with 1 company, including Carewell Steuart Pharma Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Carewell Steuart Pharma Private Limited at ₹24.50 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Carewell Steuart Pharma Private Limited U74990TN2008PTC070035 | Additional Director | 24 Jan 2026 | 2008 | ₹24.50 Cr (FY 2025) | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Dhandapani Lokesh
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dhandapani Lokesh
Dhandapani Lokesh has experience in corporate governance. Holds Additional Director role. Currently with 1 company, including Carewell Steuart Pharma Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Carewell Steuart Pharma Private Limited at ₹24.50 Cr (FY 2025).
Dhandapani Lokesh is associated with 1 company as Additional Director, including Carewell Steuart Pharma Private Limited (₹24.50 Cr).
Dhandapani Lokesh has expertise in General Business.
Dhandapani Lokesh has extensive experience in corporate governance.
By reported revenue, the largest current company of Dhandapani Lokesh is Carewell Steuart Pharma Private Limited, with revenue of ₹24.50 Cr (FY 2025).
Dhandapani Lokesh currently holds positions at 1 company: Carewell Steuart Pharma Private Limited (₹24.50 Cr).